129 related articles for article (PubMed ID: 37121805)
1. Considerations for unblinding individual study participants during vaccine trials.
Halsey N; Evans S; Santosham M; Hacker A; Edwards KM; Chandler RE; Dudley MZ; Dekker CL; ; Al-Abri S; Arora N; Buttery J; Dodoo A; Eskola J; Heininger U; Jee Y; Khuri N; Obaro S; Orenstein W; Pitisuttithum P; Safadi M; Whitney CG; Black S
Vaccine; 2023 May; 41(22):3399-3402. PubMed ID: 37121805
[TBL] [Abstract][Full Text] [Related]
2. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
4. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
6. The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications.
Bello S; Moustgaard H; Hróbjartsson A
J Clin Epidemiol; 2014 Oct; 67(10):1059-69. PubMed ID: 24973822
[TBL] [Abstract][Full Text] [Related]
7. Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?
Gray GE; Metch B; Churchyard G; Mlisana K; Nchabeleng M; Allen M; Moodie Z; Kublin J; Bekker LG;
Vaccine; 2013 Apr; 31(16):2089-96. PubMed ID: 23370155
[TBL] [Abstract][Full Text] [Related]
8. Smallpox vaccination and adverse reactions. Guidance for clinicians.
Cono J; Casey CG; Bell DM;
MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
[TBL] [Abstract][Full Text] [Related]
9. Nicotine vaccines for smoking cessation.
Hartmann-Boyce J; Cahill K; Hatsukami D; Cornuz J
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD007072. PubMed ID: 22895958
[TBL] [Abstract][Full Text] [Related]
10. Needle size for vaccination procedures in children and adolescents.
Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010720. PubMed ID: 30091147
[TBL] [Abstract][Full Text] [Related]
11. Needle size for vaccination procedures in children and adolescents.
Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
13. Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series.
Martínez-Lavín M; Amezcua-Guerra L
Clin Rheumatol; 2017 Oct; 36(10):2169-2178. PubMed ID: 28730271
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Adverse Events Following Childhood Immunizations in Pinar del Río, Cuba.
Cruz-Rodríguez E; Galindo-Santana BM; Baldoquín-Rodríguez W; Concepción-Díaz D; Luis-Martínez MC
MEDICC Rev; 2021 Jan; 23(1):35-42. PubMed ID: 33780421
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-related adverse events in Cuban children, 1999-2008.
Galindo BM; Concepción D; Galindo MA; Pérez A; Saiz J
MEDICC Rev; 2012 Jan; 14(1):38-43. PubMed ID: 22334111
[TBL] [Abstract][Full Text] [Related]
16. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
Varricchio F; Iskander J; Destefano F; Ball R; Pless R; Braun MM; Chen RT
Pediatr Infect Dis J; 2004 Apr; 23(4):287-94. PubMed ID: 15071280
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
18. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
[TBL] [Abstract][Full Text] [Related]
19. Considerations on immunization anxiety-related reactions in clusters.
Palacios R
Colomb Med (Cali); 2014; 45(3):136-40. PubMed ID: 25386041
[TBL] [Abstract][Full Text] [Related]
20. Adverse Events Following the First Dose of Immunization of COVID-19 Vaccine.
Bhandari B; Jha N; Khan IH; Rayamajhi G; Thapa L; Bista B
J Nepal Health Res Counc; 2022 Jun; 20(1):59-64. PubMed ID: 35945854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
